Babak Benjamin Navi

Babak Benjamin Navi

Auto-generated profile, based on publicly available information

Babak Benjamin Navi

Weill Cornell Medicine

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in JACC
Verified
Journal Article
Closed access
BNBabak B. Navi
Babak B. Navi
ARAnne S. Reiner
Anne S. Reiner
HKHooman Kamel
Hooman Kamel
CICostantino Iadecola
Costantino Iadecola
POPeter M. Okin
Peter M. Okin
LDLisa M. DeAngelis
Lisa M. DeAngelis

1 November 2020 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AMAlexander E. Merkler
Alexander E. Merkler
NPNeal S. Parikh
Neal S. Parikh
SMSaad Mir
Saad Mir
AGAjay Gupta
Ajay Gupta
HKHooman Kamel
Hooman Kamel
BNBabak B. Navi
Babak B. Navi
Coronavirus disease 2019 (COVID-19) has affected more than 8 million people and caused 440 000 deaths worldwide.1 Although COVID-19 is primarily a respiratory illness, reports suggest that it may lead to a hypercoagulable state and thrombotic complications.2-4 Recent publications from China, France, and New York raise the possibility that COVID-19 might increase the risk of ischemic stroke.5-8 However, these studies lacked appropriate control groups. To evaluate whether COVID-19 is associated with a higher rate of ischemic stroke than would generally be expected from a viral respiratory infection, we compared the likelihood of acute ischemic stroke in patients with COVID-19 vs patients with influenza, a known stroke risk factor.9

3 April 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HKHooman Kamel
Hooman Kamel
BNBabak B. Navi
Babak B. Navi
NSNandita Sriram
Nandita Sriram
DHDominic A. Hovsepian
Dominic A. Hovsepian
RDRichard B. Devereux
Richard B. Devereux
MEMitchell S.V. Elkind
Mitchell S.V. Elkind
The postpartum state is associated with a substantially increased risk of thrombosis. It is uncertain to what extent this heightened risk persists beyond the conventionally defined 6-week postpartum period. Using claims data on all discharges from nonfederal emergency departments and acute care hospitals in California, we identified women who were hospitalized for labor and delivery between January 1, 2005, and June 30, 2010. We used validated diagnosis codes to identify a composite primary outcome of ischemic stroke, acute myocardial infarction, or venous thromboembolism. We then used conditional logistic regression to assess each patient's likelihood of a first thrombotic event during sequential 6-week periods after delivery, as compared with the corresponding 6-week period 1 year later. Among the 1,687,930 women with a first recorded delivery, 1015 had a thrombotic event (248 cases of stroke, 47 cases of myocardial infarction, and 720 cases of venous thromboembolism) in the period of 1 year plus up to 24 weeks after delivery. The risk of primary thrombotic events was markedly higher within 6 weeks after delivery than in the same period 1 year later, with 411 events versus 38 events, for an absolute risk difference of 22.1 events (95% confidence interval [CI], 19.6 to 24.6) per 100,000 deliveries and an odds ratio of 10.8 (95% CI, 7.8 to 15.1). There was also a modest but significant increase in risk during the period of 7 to 12 weeks after delivery as compared with the same period 1 year later, with 95 versus 44 events, for an absolute risk difference of 3.0 events (95% CI, 1.6 to 4.5) per 100,000 deliveries and an odds ratio of 2.2 (95% CI, 1.5 to 3.1). Risks of thrombotic events were not significantly increased beyond the first 12 weeks after delivery. Among patients in our study, an elevated risk of thrombosis persisted until at least 12 weeks after delivery. However, the absolute increase in risk beyond 6 weeks after delivery was low. (Funded by the National Institute of Neurological Disorders and Stroke.)

1 March 2011 in Critical Care Medicine
Verified
Journal Article
Closed access
HKHooman Kamel
Hooman Kamel
BNBabak B. Navi
Babak B. Navi
KNKazuma Nakagawa
Kazuma Nakagawa
JHJ. Claude Hemphill
J. Claude Hemphill
NKNerissa U. Ko
Nerissa U. Ko
Randomized trials have suggested that hypertonic saline solutions may be superior to mannitol for the treatment of elevated intracranial pressure, but their impact on clinical practice has been limited, partly by their small size. We therefore combined their findings in a meta-analysis. We searched for relevant studies in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and ISI Web of Knowledge. Randomized trials were included if they directly compared equiosmolar doses of hypertonic sodium solutions to mannitol for the treatment of elevated intracranial pressure in human subjects undergoing quantitative intracranial pressure measurement. Two investigators independently reviewed potentially eligible trials and extracted data using a preformed data collection sheet. Disagreements were resolved by consensus or by a third investigator if needed. We collected data on patient demographics, type of intracranial pathology, baseline intracranial pressure, osms per treatment dose, quantitative change in intracranial pressure, and prespecified adverse events. Our primary outcome was the proportion of successfully treated episodes of elevated intracranial pressure. Five trials comprising 112 patients with 184 episodes of elevated intracranial pressure met our inclusion criteria. In random-effects models, the relative risk of intracranial pressure control was 1.16 (95% confidence interval, 1.00-1.33), and the difference in mean intracranial pressure reduction was 2.0 mm Hg (95% confidence interval, -1.6 to 5.7), with both favoring hypertonic saline over mannitol. A mild degree of heterogeneity was present among the included trials. There were no significant adverse events reported. We found that hypertonic saline is more effective than mannitol for the treatment of elevated intracranial pressure. Our meta-analysis is limited by the small number and size of eligible trials, but our findings suggest that hypertonic saline may be superior to the current standard of care and argue for a large, multicenter, randomized trial to definitively establish the first-line medical therapy for intracranial hypertension.

30 April 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
BNBabak B. Navi
Babak B. Navi
CICostantino Iadecola
Costantino Iadecola

4 December 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
BNBabak B. Navi
Babak B. Navi
ARAnne S. Reiner
Anne S. Reiner
HKHooman Kamel
Hooman Kamel
CICostantino Iadecola
Costantino Iadecola
MEMitchell S. V. Elkind
Mitchell S. V. Elkind
LDLisa M. DeAngelis
Lisa M. DeAngelis